These findings indicate that TLR9 signaling leads to tumor progression, which may be highly related to STAT3 activation in the tumor microenvironment, but the mechanism by which TLR9 signaling activates STAT3 in cancer cells to inhibit antitumor immunity is poorly understood. This evidence concerns the gene STAT3 and cancer.